Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The British Heart Foundation has awarded a total of £7.6 million to research programmes at the world-leading Burdon Sanderson Cardiac Science Centre in the Department of Physiology, Anatomy and Genetics

Awardees : Left to right Dr Sarah De Val (BHF Senior Fellow), Dr Duncan Sparrow (BHF Senior Fellow), Associate Professor Pawel Swietach (BHF Programme Director), BHF Professor Paul Riley, Director of Regenerative Medicine Centre, Professor Manuela Zaccolo (BHF Programme Director & Director of Cardiac Centre), Dr Lisa Heather (BHF Intermediate Fellow),  Dr Samira Lakhal-Littleton (BHF Intermediate Fellow) & Professor David Paterson (BHF Programme Director & Head of Department).  

The BHF investment highlights the excellent quality of research, at the forefront of cardiac science today, which is carried out at the Burdon Sanderson Cardiac Science Centre. Embedded in the Oxford Cardiovascular Science network, we are grateful to the BHF Centre for Research Excellence, led by Professor Hugh Watkins, for start-up funding which enabled some of our awards.

Professor David Paterson, Head of the Department of Physiology, Anatomy and Genetics, commented: ‘Cardiac science is one of the main research themes in the Department, and this current funding is testament to the quality of the work undertaken by the 90 scientists in the Burdon Sanderson Cardiac Science Centre’.

Read more (Department of Physiology, Anatomy, and Genetics website)

British Heart Foundation 

British Heart Foundation.jpg

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Clinical Trials Coronavirus COVID-19 General Research

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.